EazeBio, a biotechnology company focused on developing scalable, patient-centric solutions, has announced a strategic partnership with the University of California, Santa Cruz (UC Santa Cruz) to co-develop an innovative cortisol biosensor for stress and metabolic health testing.
Combining EazeBio’s expertise in affordable, scalable biotechnology with UC Santa Cruz’s deep research capabilities, they aim to accelerate the development of next-generation, laboratory independent testing for global health applications.
The partnership represents a key milestone in EazeBio’s mission to democratise access to clinical-grade testing, bringing rapid diagnostics to the point of care in both developed and resource-limited settings. Together, EazeBio and UC Santa Cruz aim to address some of the world’s most urgent health challenges by focusing on translating academic breakthroughs into real-world solutions that enable earlier detection, faster treatment, and improved health outcomes.
"At EazeBio, we are committed to transforming the way diagnostics reach people," said Reem Mahrat, CEO and Founder of EazeBio (pictured). "Our partnership with UC Santa Cruz brings together world-class science and mission-driven innovation to create a platform built not just for performance - but for global health equity. This latest technology brings the laboratory to the patient, not the other way around."
Rooted in UC Santa Cruz’s cutting-edge biosensing research and inspired by Nobel Prize-winning science, the platform represents a significant leap forward in point-of-care diagnostics combining innovative detection chemistry with luminescent biosensors, modular assay design, and AI-guided interpretation. It’s engineered for speed, affordability, and accessibility; requiring no instrumentation, refrigeration, or specialised training. The result: laboratory quality performance without the need for traditional laboratory infrastructure.
Designed for real-world deployment in both high-resource and underserved settings, this flexible system can be rapidly customised for a wide range of applications, including:
- Antimicrobial resistance (AMR) detection
- Viral outbreak response (eg influenza, RSV, novel coronaviruses)
- Hormonal monitoring (eg cortisol, fertility, stress, endocrine disorders)
- Cancer biomarker detection for early-stage screening
- Biothreat and emergency response in public health scenarios.